These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37847485)

  • 1. Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
    Zhao M; Qiu S; Wu X; Miao P; Jiang Z; Zhu T; Xu X; Zhu Y; Zhang B; Yuan D; Zhang Y; Sun W; He A; Zhao M; Hou W; Zhang Y; Shao Z; Jia M; Li M; Chen J; Xu J; Chen B; Zhou Y; Shen Y
    Target Oncol; 2023 Nov; 18(6):869-883. PubMed ID: 37847485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 3. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
    Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR
    Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
    Shi T; Yin S; Zhu J; Zhang P; Liu J; Zhu Y; Wu S; Chen X; Wang X; Teng Y; Zhu T; Yu A; Zhang Y; Feng Y; Huang H; Bao W; Li Y; Jiang W; Zhang P; Li J; Ai Z; Zhang W; Jia H; Zhang Y; Jiang R; Zhang J; Gao W; Luan Y; Zang R
    J Gynecol Oncol; 2020 May; 31(3):e61. PubMed ID: 32319233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
    Musacchio L; Palluzzi E; Di Napoli M; Lauria R; Ferrandina G; Angioli R; Bergamini A; Corrado G; Perniola G; Cassani C; Savarese A; Gori S; Greco F; De Angelis C; Zafarana E; Giannarelli D; Cinieri S; Mosconi AM; Raspagliesi F; Pignata S; Scambia G; Lorusso D
    Gynecol Oncol; 2024 May; 184():24-30. PubMed ID: 38277918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
    Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
    Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
    Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
    Kim JH; Kim SI; Park EY; Kim ET; Kim H; Kim S; Park SY; Lim MC
    Gynecol Oncol; 2024 Feb; 181():33-39. PubMed ID: 38104527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
    Lee A
    Target Oncol; 2021 Nov; 16(6):839-845. PubMed ID: 34635996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
    Li N; Zhu J; Yin R; Wang J; Pan L; Kong B; Zheng H; Liu J; Wu X; Wang L; Huang Y; Wang K; Zou D; Zhao H; Wang C; Lu W; Lin A; Lou G; Li G; Qu P; Yang H; Zhang Y; Cai H; Pan Y; Hao M; Liu Z; Cui H; Yang Y; Yao S; Zhen X; Hang W; Hou J; Wang J; Wu L
    JAMA Oncol; 2023 Sep; 9(9):1230-1237. PubMed ID: 37440217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niraparib treatment for patients with
    González-Martín A; Matulonis UA; Korach J; Mirza MR; Moore KN; Wu X; York W; Gupta D; Lechpammer S; Monk BJ
    Future Oncol; 2022 Jul; 18(23):2505-2536. PubMed ID: 35791804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
    Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
    Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
    Cueva JF; Palacio I; Churruca C; Herrero A; Pardo B; Constenla M; Santaballa A; Manso L; Estévez P; Maximiano C; Legerén M; Marquina G; de Juan A; Quindós M; Sánchez L; Barquin A; Fernández I; Martín C; Juárez A; Martín T; García Y; Yubero A; Gallego A; Martínez Bueno A; Guerra E; González-Martín A
    Eur J Cancer; 2023 Mar; 182():3-14. PubMed ID: 36706655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
    Ni J; Cheng X; Zhao Q; Dai Z; Xu X; Guo W; Gu H; Zhou R; Wang Y; Chen X
    J Ovarian Res; 2021 May; 14(1):68. PubMed ID: 33993885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA
    Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
    Ai X; Pan Y; Shi J; Yang N; Liu C; Zhou J; Zhang X; Dong X; He J; Li X; Chen G; Li X; Zhang H; Liao W; Zhang Y; Ma Z; Jiang L; Cui J; Hu C; Wang W; Huang C; Zhao J; Ding C; Hu X; Wang K; Gao B; Song Y; Liu X; Xiong J; Liu A; Li J; Liu Z; Li Y; Wang M; Zhang B; Zhang D; Lu S
    J Thorac Oncol; 2021 Aug; 16(8):1403-1414. PubMed ID: 33915252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.